Poor
Not Aligned
Patient Risk:
High
Summary
Most extracted claims are not supported by the FDA label text provided in the prompt; only hypersensitivity occurrence is supported by the included 5.1 excerpt. Many dosing, indication, timing, pediatric/prophylaxis, pregnancy/breastfeeding, testing, trial identity, adverse events, and exclusivity claims cannot be verified against the supplied label excerpts.
Category Scores
Accurate Statements
Hypersensitivity reactions can occur with Xofluza.
Supported by provided label excerpt in 5.1 Hypersensitivity (e.g., anaphylaxis, urticaria, angioedema, erythema multiforme).
Unsupported Statements
Xofluza (baloxavir marboxil) is FDA-approved for treating acute uncomplicated influenza in patients 5 years and older who have been symptomatic for no more than 48 hours.
The provided label excerpts do not include Indications language with age (≥5 years) or the ≤48 hours symptomatic limitation.
Xofluza is approved for post-exposure prophylaxis in patients 5 years and older during an influenza outbreak.
No prophylaxis/outbreak and ≥5 years age-criterion text is present in the provided excerpts.
Xofluza is not approved for children under 5 years old.
The provided excerpts reference Pediatric Use (8.4) but do not include the under-5 limitation/approval boundary.
Clinical trials have not established safety and efficacy of Xofluza in children under 5 years old.
No provided excerpt includes under-5 safety/efficacy establishment language.
The FDA label limits Xofluza use to ages 5 and up.
No provided excerpt includes a label scope/age limitation statement.
Approval for ages 5–11 was based on the miniSTONE-2 trial.
Only a Clinical Studies (14) header is provided; no study details/names or basis for approval are included.
In the miniSTONE-2 trial, Xofluza reduced influenza symptoms comparably to oseltamivir in 1,160 children.
No clinical study results, comparator details, or sample size are included in the provided excerpts.
For ages 12 and older, data from the CAPSTONE-1 trial supported Xofluza.
No CAPSTONE-1 or age-stratified trial evidence is included in the provided excerpts.
Xofluza dosing is weight-based.
The provided dosage excerpt lists tablet strengths and suspension presentations but does not state that dosing is weight-based.
Xofluza is dosed as a single 40 mg dose for 20–79 kg body weight.
The provided excerpts do not include weight-range dosing or the stated single-dose regimen.
Xofluza is dosed as an 80 mg dose for 80 kg or more.
The provided excerpts do not include the ≥80 kg dosing threshold.
Off-label use of Xofluza in children under 5 occurs rarely.
No provided label excerpt discusses off-label usage frequency.
Off-label use in children under 5 is due to limited data and potential risks like adverse events seen in trials.
No provided excerpt discusses off-label rationale or links under-5 use to specific trial adverse events.
Adverse events seen in trials of Xofluza include diarrhea and vomiting.
The provided excerpts do not include clinical adverse reaction details from 6 Adverse Reactions (only a reference/link is present).
Xofluza is not recommended during pregnancy or breastfeeding due to insufficient data.
Pregnancy (8.1) and Lactation (8.2) sections are referenced, but the provided excerpt text does not contain recommendations or “insufficient data” statements.
Influenza should be confirmed via testing before use of Xofluza.
No provided excerpt includes guidance requiring influenza confirmation by testing before use.
The phase 3 CR831 study is testing Xofluza in children 1–5 years old for treatment and prophylaxis.
No study identifiers (CR831) or development/test design statements are present in the provided excerpts.
Results from the CR831 study could potentially support label expansion by 2025.
No provided excerpt discusses timelines for label expansion.
Roche/Genentech holds U.S. exclusivity until at least 2031 for Xofluza.
No provided label excerpt includes regulatory/commercial exclusivity dates.
Contradictions
Important Omissions
If evaluating contraindications/warnings beyond hypersensitivity, the prompt did not include Contraindications (4) or other Warnings/Precautions content (beyond the 5.1 hypersensitivity excerpt).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Multiple label-critical claims (indication/age and time limitation, prophylaxis, pregnancy/lactation recommendation, and dosing by weight) are not supported by the provided label excerpts; an incorrect label-alignment assessment could misrepresent safe and approved use criteria.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
The majority of claims are not verifiable from the provided FDA label excerpts, including core approval indications and dosing specifics.
Suggested Improvement
Limit claims to text explicitly present in the provided label excerpts (e.g., 2.1 dosing form info, 5.1 hypersensitivity). Provide full relevant label sections (Indications 1, Dosage 2.2/2.3/2.4, Limitations of Use 1.3, Contraindications 4, Warnings/Precautions 5, Pediatric 8.4, Pregnancy 8.1/Lactation 8.2, Adverse Reactions 6) if deeper verification is required.